Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Semaglutide Linked to 40% Fewer Asthma Attacks

Analysis based on 22 articles · First reported Sep 07, 2026 · Last updated Sep 24, 2026

Sentiment
15
Attention
4
Articles
22
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study could broaden the perceived therapeutic profile of semaglutide beyond diabetes and obesity, potentially supporting longer-term demand expectations for Novo Nordisk's GLP-1 franchise. However, because the findings are observational and researchers explicitly warn against changing prescribing guidance, any near-term revenue impact is likely limited and sentiment-driven.

pharmaceuticals healthcare biotechnology

A real-world study led by Professor Chloe Bloom of the National Heart & Lung Institute at Imperial College London, and presented by Dr Bohee Lee, found that semaglutide, the active ingredient in Ozempic and Wegovy, was associated with nearly 40% fewer asthma attacks and a 20% reduction in COPD flare-ups. The research was presented at the European Respiratory Society Congress in Spain — Barcelona, Spain. The team analyzed UK electronic medical records across four parallel studies, each involving 20,000 to 22,000 people who had started a GLP-1 medication or a sulfonylurea. Among the GLP-1 drugs examined, only semaglutide showed a significant association, with the strongest effect in people with asthma. Researchers cautioned that the observational findings do not prove causation and should not change prescribing guidance; clinical trials are needed. Dr Alexander Mathioudakis of the University of Manchester and the European Respiratory Society noted the study highlights metabolic health in respiratory care. Dr List of Home and Away characters introduced in 1989 of Asthma + Lung UK called the results promising, particularly for patients with obesity or diabetes.

80 Chloe Bloom presented study
60 Bohee Lee presented study
40 European Respiratory Society hosted congress
25 Alexander Mathioudakis called for clinical trials
15 List of Home and Away characters introduced in 1989 called results promising
stock
Maker of Ozempic and Wegovy, the semaglutide products involved; positive respiratory findings could support demand expectations, though no prescribing change is recommended yet.
Importance 70.0 Sentiment 20.0
per
Lead researcher who presented the findings and emphasized they should not change treatment decisions without clinical trial confirmation.
Importance 65.0 Sentiment 10.0
ngo
Hosted the congress in Spain — Barcelona where the findings were presented, serving as the scientific platform for the study.
Importance 50.0 Sentiment 5.0
cnt
Source of the electronic medical records analyzed, covering tens of thousands of patients, which underpins the study's real-world evidence.
Importance 40.0 Sentiment 5.0
per
Presented the study at the European Respiratory Society Congress.
Importance 30.0 Sentiment 5.0
per
Independent expert who highlighted the need to include respiratory outcomes in future metabolic therapy trials.
Importance 30.0 Sentiment 5.0
loc
Host city of the European Respiratory Society Congress where the research was presented.
Importance 20.0 Sentiment 0.0
ngo
Charity whose representative called the results promising, particularly for asthma patients with obesity or diabetes.
Importance 20.0 Sentiment 5.0
per
Asthma + Lung UK representative who described the results as promising for patients with obesity or diabetes.
Importance 20.0 Sentiment 5.0
cnt
Country hosting the medical congress at which the findings were announced.
Importance 15.0 Sentiment 0.0
United Kingdom related ↔ Spain
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.